

### Transcript Details

This is a transcript of a continuing medical education (CME) activity. Additional media formats for the activity and full activity details (including sponsor and supporter, disclosures, and instructions for claiming credit) are available by visiting:

<https://reachmd.com/programs/cme/nivo-and-rela-versus-nivo-in-previously-untreated-metastatic-or-unresectable-melanoma-additional-response-outcomes-from-relativity-047/14455/>

Released: 09/30/2022

Valid until: 09/30/2023

Time needed to complete: 39m

### ReachMD

[www.reachmd.com](http://www.reachmd.com)

[info@reachmd.com](mailto:info@reachmd.com)

(866) 423-7849

---

NIVO and RELA versus NIVO in Previously Untreated Metastatic or Unresectable Melanoma: Additional Response Outcomes from RELATIVITY-047

### Announcer:

Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum.

Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.

### Dr. Luke:

Hi, I'm Jason Luke from the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania. Today, we're reviewing the high-impact abstracts presented at ESMO 2022, with one of those being the update to RELATIVITY-047, to RELATIVITY-047, the randomized phase three trial of nivolumab and relatlimab has compared with nivolumab alone, and frontline treatment-naive metastatic melanoma.

These data have been updated a few times since presentation about a year and a half ago. Just to emphasize that these were practice-changing data, with a major improvement in the progression-free survival at 10.2 months for the combination as compared to 4.6 months for monotherapy. With the response rate being approximately 10% greater as well, 43% for the combination versus 32.6% for monotherapy nivolumab.

Now, in the update at ESMO 2022, what the authors showed was that the overall best reduction in overall tumor burden comparison for the combo of nivolumab and relatlimab was 80.3% as compared with nivolumab at 72.3%. They broke down the best overall response by quality of response for the combination versus nivolumab, showing as expected that those patients who had a complete response, or partial response, had better long term outcomes relative to patients who had only stable disease, or progression of disease.

The toxicity profile for this combination was essentially unchanged, noting that treatment related high grade immune related adverse events were about 11% for nivolumab as compared to 21% for nivolumab and relatlimab.

Overall, these are important data as this is a new combination that's impacted the frontline standard of care in melanoma. These data really reinforced the clinical benefit of nivolumab and relatlimab in patients with advanced melanoma. I'd like to thank you for joining us today in this review of the RELATIVITY-047 trial, and the abstracts from ESMO 2022.

### Announcer:

You have been listening to CME on ReachMD. This activity is jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc. and is part of our MinuteCME curriculum.

To receive your free CME credit, or to download this activity, go to [ReachMD.com/CME](http://ReachMD.com/CME). Thank you for listening.